490 related articles for article (PubMed ID: 22765220)
1. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
2. Six1 promotes epithelial-mesenchymal transition and malignant conversion in human papillomavirus type 16-immortalized human keratinocytes.
Xu H; Zhang Y; Altomare D; Peña MM; Wan F; Pirisi L; Creek KE
Carcinogenesis; 2014 Jun; 35(6):1379-88. PubMed ID: 24574515
[TBL] [Abstract][Full Text] [Related]
3. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties.
Farabaugh SM; Micalizzi DS; Jedlicka P; Zhao R; Ford HL
Oncogene; 2012 Feb; 31(5):552-62. PubMed ID: 21706047
[TBL] [Abstract][Full Text] [Related]
4. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer.
Smith AL; Iwanaga R; Drasin DJ; Micalizzi DS; Vartuli RL; Tan AC; Ford HL
Oncogene; 2012 Dec; 31(50):5162-71. PubMed ID: 22286770
[TBL] [Abstract][Full Text] [Related]
5. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.
Micalizzi DS; Christensen KL; Jedlicka P; Coletta RD; Barón AE; Harrell JC; Horwitz KB; Billheimer D; Heichman KA; Welm AL; Schiemann WP; Ford HL
J Clin Invest; 2009 Sep; 119(9):2678-90. PubMed ID: 19726885
[TBL] [Abstract][Full Text] [Related]
6. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
7. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.
Micalizzi DS; Wang CA; Farabaugh SM; Schiemann WP; Ford HL
Cancer Res; 2010 Dec; 70(24):10371-80. PubMed ID: 21056993
[TBL] [Abstract][Full Text] [Related]
8. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.
McCoy EL; Iwanaga R; Jedlicka P; Abbey NS; Chodosh LA; Heichman KA; Welm AL; Ford HL
J Clin Invest; 2009 Sep; 119(9):2663-77. PubMed ID: 19726883
[TBL] [Abstract][Full Text] [Related]
9. NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro.
Simmons MJ; Serra R; Hermance N; Kelliher MA
Breast Cancer Res; 2012 Sep; 14(5):R126. PubMed ID: 22992387
[TBL] [Abstract][Full Text] [Related]
10. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
11. Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3β activities.
Choi HY; Yang GM; Dayem AA; Saha SK; Kim K; Yoo Y; Hong K; Kim JH; Yee C; Lee KM; Cho SG
Breast Cancer Res; 2019 Jan; 21(1):6. PubMed ID: 30651129
[TBL] [Abstract][Full Text] [Related]
12. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
13. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.
Wilson CA; Cajulis EE; Green JL; Olsen TM; Chung YA; Damore MA; Dering J; Calzone FJ; Slamon DJ
Breast Cancer Res; 2005; 7(6):R1058-79. PubMed ID: 16457687
[TBL] [Abstract][Full Text] [Related]
14. FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells.
Kim S; Dubrovska A; Salamone RJ; Walker JR; Grandinetti KB; Bonamy GM; Orth AP; Elliott J; Porta DG; Garcia-Echeverria C; Reddy VA
PLoS One; 2013; 8(1):e51671. PubMed ID: 23300950
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
[TBL] [Abstract][Full Text] [Related]
16. COX-2 induces oncogenic micro RNA miR655 in human breast cancer.
Majumder M; Dunn L; Liu L; Hasan A; Vincent K; Brackstone M; Hess D; Lala PK
Sci Rep; 2018 Jan; 8(1):327. PubMed ID: 29321644
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?
Tan AR; Alexe G; Reiss M
Breast Cancer Res Treat; 2009 Jun; 115(3):453-95. PubMed ID: 18841463
[TBL] [Abstract][Full Text] [Related]
18. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
[TBL] [Abstract][Full Text] [Related]
19. SIX1 maintains tumor basal cells via transforming growth factor-β pathway and associates with poor prognosis in esophageal cancer.
Nishimura T; Tamaoki M; Komatsuzaki R; Oue N; Taniguchi H; Komatsu M; Aoyagi K; Minashi K; Chiwaki F; Shinohara H; Tachimori Y; Yasui W; Muto M; Yoshida T; Sakai Y; Sasaki H
Cancer Sci; 2017 Feb; 108(2):216-225. PubMed ID: 27987372
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.
Zhou H; Blevins MA; Hsu JY; Kong D; Galbraith MD; Goodspeed A; Culp-Hill R; Oliphant MUJ; Ramirez D; Zhang L; Trinidad-Pineiro J; Mathews Griner L; King R; Barnaeva E; Hu X; Southall NT; Ferrer M; Gustafson DL; Regan DP; D'Alessandro A; Costello JC; Patnaik S; Marugan J; Zhao R; Ford HL
Cancer Res; 2020 Jun; 80(12):2689-2702. PubMed ID: 32341035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
